CRF Bracket closes its first full quarter as a combined entity with more than a 20% increase in new clinical trial business – and will “aggressively look for partners” from its current and future customers, says CEO.
Drug development advisory firm Rosa & Co. enters research agreement with Chugai pharmaceutical to provide access to PhysioPD research services for translational biology.
The oncology-focused alliance brings together Worldwide’s cancer research and clinical trial operations with Deep Lens’ Viper digital pathology platform.
The non-clinical contract research services and research model provider Envigo launches a new solution it says optimizes non-clinical safety assessment programs to enable first-in-human clinical trials.
Regeneron and UK Biobank announce human sequencing data resource for global research and to accelerate improved patient care through outcome algorithms.
Datathon participants identify five repurposable drug candidates, applying AI to identify genes of interest and support target identification – a task that previously would have taken years, says industry expert.
It is critical to understand the patient and site perspective to “maximize opportunities and minimize challenges” associated with the use of mobile technology in clinical trials, says CTTI executive director.
Genentech receives US FDA approval on Herceptin Hylecta, a subcutaneous co-formulation using Halozyme’s recombinant Enhanze technology, for the treatment of HER2-positive metastatic breast cancer.
Akorn announces fraud case launched by Fresenius has been denied by US courts, shortly after fourth quarter financials revealed problems within its manufacturing network.
The institutional review board industry sees further consolidation as Advarra acquires Quorum and its research and technology consulting division, Kinetiq.
Camber and Macleods voluntarily recall losartan tablets lots, after trace amounts of a possible carcinogen found in an API ingredient manufactured at the same third-party facility.
TrialAssure releases anonymizing SaaS to enable sponsors to share clinical trial data, as the industry shifts towards utilizing big data while maintaining patient privacy.
Novartis Pharma AG partners with Target PharmaSolutions to support its global longitudinal observational study designed to generate real-world clinical data.
Parexel boosts its oncology team, Premier Research has a new COO joining from PPD, and SGS names a new biologics manager, among other new hires in February.
Alphabet's research organization Verily is on a mission to empower patients with their own data – and to collectively solve some of the industry’s biggest challenges, says SCOPE keynote speaker.
Houston Methodist Hospital joins the TriNetX global health research network to provide RWD for study feasibility and academic collaboration in industry-sponsored clinical trials.
Artificial intelligence works best in a standardized environment, say industry experts. Workflows and processes must first be aligned to successfully use the technology – is pharma ready?
Integrated research organizations aim to bridge the gap between clinical research and clinical health care with the use of RWD, yet, the data may not be ready for research, according to Elligo Data Scientist.
Inclusion criteria, standardized procedures, and high-quality clinician training are key to conducting clinical trials in individuals with autism spectrum disorder, says industry expert.
The goal of the learning health system is to improve based on the experiences of every participant, sharing research knowledge to drive a “person-centered future of health,” says LHC CEO.
Why do people do what they do? This is the question behavioral science aims to answer – and our understanding of which is directly relevant to the challenges facing the health care industry, says industry expert.
A pre-IND review by the US FDA has allowed Virpax to continue with NDAs for DSF100 and LBL100, two pain relief products with specialised drug delivery formulations.
A drug is only as effective as its delivery system, and the advent of new molecules and new innovations have to be matched by enhanced delivery and containment methods, suggests West Pharma exec.
Consolidating its businesses under one brand, Altasciences is transitioning to an early drug development CRO – and looking to add a CDMO to manufacture drugs up to Phase II volumes.
